Almirall and IRB Barcelona team up to tackle skin disease
pharmaphorum
JANUARY 18, 2022
Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Almirall and IRB Barcelona (the Institute for Research in Biomedicine), will conduct research using molecular glue degraders, a new approach to the skin diseases under scrutiny.
Let's personalize your content